| scholarly article | Q13442814 |
| P50 | author | Joseph Sodroski | Q64524473 |
| Peter D. Kwong | Q68690794 | ||
| Richard T. Wyatt | Q96247131 | ||
| P2093 | author name string | W A Hendrickson | |
| J Robinson | |||
| R W Sweet | |||
| S Majeed | |||
| P2860 | cites work | Biologically diverse molecular variants within a single HIV-1 isolate | Q57998184 |
| Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS) | Q22242256 | ||
| The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens | Q22242262 | ||
| HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor | Q22242268 | ||
| Identification of a major co-receptor for primary isolates of HIV-1 | Q22251282 | ||
| Energetics of the HIV gp120-CD4 binding reaction | Q22254716 | ||
| Dimeric association and segmental variability in the structure of human CD4 | Q24324340 | ||
| Improved methods for building protein models in electron density maps and the location of errors in these models | Q26776980 | ||
| Crystallography & NMR System: A New Software Suite for Macromolecular Structure Determination | Q26778405 | ||
| MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures | Q26778412 | ||
| Processing of X-ray diffraction data collected in oscillation mode | Q26778468 | ||
| Structural studies of two rhinovirus serotypes complexed with fragments of their cellular receptor | Q27620392 | ||
| Structural analysis of the mechanism of adenovirus binding to its human cellular receptor, CAR | Q27620424 | ||
| Interaction of the poliovirus receptor with poliovirus | Q27620834 | ||
| Structures of an HIV and MHC binding fragment from human CD4 as refined in two crystal lattices | Q27730898 | ||
| Kinetic and structural analysis of mutant CD4 receptors that are defective in HIV gp120 binding | Q27734294 | ||
| Core structure of gp41 from the HIV envelope glycoprotein | Q27736064 | ||
| Atomic structure of the ectodomain from HIV-1 gp41 | Q27738021 | ||
| Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody | Q27759364 | ||
| Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons | Q27861091 | ||
| A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors | Q28118386 | ||
| The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus | Q28259668 | ||
| The antigenic structure of the HIV gp120 envelope glycoprotein | Q28274698 | ||
| The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates | Q28282895 | ||
| Structure of a human common cold virus and functional relationship to other picornaviruses | Q28286689 | ||
| CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1 | Q28646859 | ||
| A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding | Q28646883 | ||
| Frequent Detection and Isolation of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and at Risk for AIDS | Q29614260 | ||
| HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5 | Q29616094 | ||
| AMoRe: an automated package for molecular replacement | Q29642803 | ||
| Atomic structure of a fragment of human CD4 containing two immunoglobulin-like domains | Q30195771 | ||
| Three-dimensional structure of poliovirus at 2.9 A resolution. | Q30196273 | ||
| Molecular characterization of biologically diverse envelope variants of human immunodeficiency virus type 1 derived from an individual | Q33379671 | ||
| Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity | Q33782556 | ||
| Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus | Q33797989 | ||
| The level of CD4 expression limits infection of primary rhesus monkey macrophages by a T-tropic simian immunodeficiency virus and macrophagetropic human immunodeficiency viruses | Q33826504 | ||
| Why protein crystals favour some space-groups over others | Q34400973 | ||
| Crystal structure of an HIV-binding recombinant fragment of human CD4. | Q34637157 | ||
| Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. | Q35841780 | ||
| Molecular characterization of human immunodeficiency virus type 1 cloned directly from uncultured human brain tissue: identification of replication-competent and -defective viral genomes | Q36796806 | ||
| Three-dimensional structure of poliovirus receptor bound to poliovirus | Q37141992 | ||
| Envelope proteins from clinical isolates of human immunodeficiency virus type 1 that are refractory to neutralization by soluble CD4 possess high affinity for the CD4 receptor | Q37588188 | ||
| Rapid selection for an N-linked oligosaccharide by monoclonal antibodies directed against the V3 loop of human immunodeficiency virus type 1. | Q38359755 | ||
| HIV-1-induced cell fusion is mediated by multiple regions within both the viral envelope and the CCR-5 co-receptor | Q38908745 | ||
| The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection | Q38949380 | ||
| Identification of envelope V3 loop as the major determinant of CD4 neutralization sensitivity of HIV-1. | Q39090313 | ||
| Intrapatient variability of HIV type 1 group O ANT70 during a 10-year follow-up. | Q39101418 | ||
| Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies | Q39579260 | ||
| V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies | Q39592261 | ||
| Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation. | Q39594428 | ||
| CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. | Q39605077 | ||
| Regulation of Oxygen Affinity of Hemoglobin: Influence of Structure of the Globin on the Heme Iron | Q39805445 | ||
| Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex | Q39878965 | ||
| Critical role of enhanced CD4 affinity in laboratory adaptation of human immunodeficiency virus type 1. | Q40870962 | ||
| The V1/V2 region of human immunodeficiency virus type 1 modulates the sensitivity to neutralization by soluble CD4 and cellular tropism | Q41085877 | ||
| Characterization of envelope and core structural gene products of HTLV-III with sera from AIDS patients | Q41936910 | ||
| Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry | Q43694761 | ||
| Probability analysis of variational crystallization and its application to gp120, the exterior envelope glycoprotein of type 1 human immunodeficiency virus (HIV-1). | Q45751477 | ||
| Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III. | Q48378749 | ||
| Characterization of gp41 as the transmembrane protein coded by the HTLV-III/LAV envelope gene. | Q55244821 | ||
| P433 | issue | 12 | |
| P921 | main subject | HIV | Q15787 |
| laboratory | Q483242 | ||
| P304 | page(s) | 1329-39 | |
| P577 | publication date | 2000-12-15 | |
| P1433 | published in | Structure | Q15709970 |
| P1476 | title | Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates | |
| P478 | volume | 8 |
| Q26851165 | A brief history of the global effort to develop a preventive HIV vaccine |
| Q34398542 | A combinatorial approach toward smart libraries of discontinuous epitopes of HIV gp120 on a TAC synthetic scaffold. |
| Q42699474 | A mechanism by which binding of the broadly neutralizing antibody b12 unfolds the inner domain α1 helix in an engineered HIV-1 gp120. |
| Q34733504 | A mechanistic understanding of allosteric immune escape pathways in the HIV-1 envelope glycoprotein |
| Q33587774 | A non-canonical binding interface in the crystal structure of HIV-1 gp120 core in complex with CD4 |
| Q40523804 | A novel assay to identify entry inhibitors that block binding of HIV-1 gp120 to CCR5. |
| Q43756667 | A rationally designed synthetic mimic of the discontinuous CD4-binding site of HIV-1 gp120. |
| Q34552313 | A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV. |
| Q35978823 | A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding |
| Q34919985 | A twin-cysteine motif in the V2 region of gp120 is associated with SIV envelope trimer stabilization |
| Q24645530 | Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1 |
| Q37593189 | Activation and Inactivation of Primary Human Immunodeficiency Virus Envelope Glycoprotein Trimers by CD4-Mimetic Compounds |
| Q36423960 | Adaptation of the human immunodeficiency virus type 1 envelope glycoproteins to new world monkey receptors |
| Q27640463 | Alternative conformations of HIV-1 V3 loops mimic beta hairpins in chemokines, suggesting a mechanism for coreceptor selectivity |
| Q34987062 | An altered and more efficient mechanism of CCR5 engagement contributes to macrophage tropism of CCR5-using HIV-1 envelopes |
| Q42086489 | An unrelated monoclonal antibody neutralizes human immunodeficiency virus type 1 by binding to an artificial epitope engineered in a functionally neutral region of the viral envelope glycoproteins |
| Q99418269 | Analysis of the SARS-CoV-2 spike protein glycan shield reveals implications for immune recognition |
| Q95611861 | Analysis of the SARS-CoV-2 spike protein glycan shield: implications for immune recognition |
| Q33223969 | Anti-HIV agents targeting the interaction of gp120 with the cellular CD4 receptor |
| Q29547345 | Antibody neutralization and escape by HIV-1 |
| Q28256508 | Antibody potency relates to the ability to recognize the closed, pre-fusion form of HIV Env |
| Q24536059 | Antibody vs. HIV in a clash of evolutionary titans |
| Q42738983 | Antibody-based HIV-1 vaccines: recent developments and future directions |
| Q30375834 | Appreciating HIV type 1 diversity: subtype differences in Env. |
| Q34121578 | AutoMatch: target-binding protein design and enzyme design by automatic pinpointing potential active sites in available protein scaffolds |
| Q33597640 | Automated detection of conformational epitopes using phage display Peptide sequences |
| Q34597300 | Back to the future: covalent epitope-based HIV vaccine development |
| Q35012342 | Binding of full-length HIV-1 gp120 to CD4 induces structural reorientation around the gp120 core |
| Q37237417 | Binding thermodynamics of the N-terminal peptide of the CCR5 coreceptor to HIV-1 envelope glycoprotein gp120 |
| Q36525116 | Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions |
| Q39240591 | Bioinformatic analysis of neurotropic HIV envelope sequences identifies polymorphisms in the gp120 bridging sheet that increase macrophage-tropism through enhanced interactions with CCR5. |
| Q36983858 | Blocking HIV-1 gp120 at the Phe43 cavity: if the extension fits… |
| Q36977635 | Broad HIV-1 neutralization mediated by CD4-binding site antibodies |
| Q35785010 | Broad-spectrum anti-human immunodeficiency virus (HIV) potential of a peptide HIV type 1 entry inhibitor |
| Q36469664 | CD4 binding determinant mimicry for HIV vaccine design |
| Q37123579 | CD4+ T cells support production of simian immunodeficiency virus Env antibodies that enforce CD4-dependent entry and shape tropism in vivo |
| Q44601067 | CD4-binding site alterations in CCR5-using HIV-1 envelopes influencing gp120-CD4 interactions and fusogenicity |
| Q37998496 | Candidate antibody-based therapeutics against HIV-1. |
| Q38154038 | Cell-to-cell spread of HIV-1 and evasion of neutralizing antibodies |
| Q34232003 | Cell-type-specific aptamer and aptamer-small interfering RNA conjugates for targeted human immunodeficiency virus type 1 therapy |
| Q33942996 | Challenges and opportunities for development of an AIDS vaccine |
| Q35914362 | Characterization and Implementation of a Diverse Simian Immunodeficiency Virus SIVsm Envelope Panel in the Assessment of Neutralizing Antibody Breadth Elicited in Rhesus Macaques by Multimodal Vaccines Expressing the SIVmac239 Envelope. |
| Q34432690 | Characterization of a discontinuous epitope of the HIV envelope protein gp120 recognized by a human monoclonal antibody using chemical modification and mass spectrometric analysis. |
| Q33717477 | Characterization of gp120 and its single-chain derivatives, gp120-CD4D12 and gp120-M9: implications for targeting the CD4i epitope in human immunodeficiency virus vaccine design |
| Q47610272 | Characterization of the conformational state and flexibility of HIV-1 glycoprotein gp120 core domain |
| Q41493875 | Characterization of the multiple conformational States of free monomeric and trimeric human immunodeficiency virus envelope glycoproteins after fixation by cross-linker |
| Q37596552 | Characterization of the outer domain of the gp120 glycoprotein from human immunodeficiency virus type 1 |
| Q35857408 | Clade-specific differences between human immunodeficiency virus type 1 clades B and C: diversity and correlations in C3-V4 regions of gp120. |
| Q35844799 | Coevolution Analysis of HIV-1 Envelope Glycoprotein Complex |
| Q27651139 | Combinatorial Optimization of a CD4-Mimetic Miniprotein and Cocrystal Structures with HIV-1 gp120 Envelope Glycoprotein |
| Q27303608 | Computational Refinement and Validation Protocol for Proteins with Large Variable Regions Applied to Model HIV Env Spike in CD4 and 17b Bound State |
| Q39195226 | Computational studies identifying entry inhibitor scaffolds targeting the Phe43 cavity of HIV-1 gp120. |
| Q35069459 | Conformational alterations in the CD4 binding cavity of HIV-1 gp120 influencing gp120-CD4 interactions and fusogenicity of HIV-1 envelopes derived from brain and other tissues |
| Q34934438 | Conformational and structural features of HIV-1 gp120 underlying the dual receptor antagonism by cross-reactive neutralizing antibody m18 |
| Q34020606 | Conformational characterization of aberrant disulfide-linked HIV-1 gp120 dimers secreted from overexpressing cells. |
| Q79968255 | Conservation of inner domain modules in the surface envelope glycoproteins of an ancient rabbit lentivirus and extant lentiviruses and betaretroviruses |
| Q34301728 | Consistent patterns of change during the divergence of human immunodeficiency virus type 1 envelope from that of the inoculated virus in simian/human immunodeficiency virus-infected macaques |
| Q36499053 | Cost-effective production of a vaginal protein microbicide to prevent HIV transmission. |
| Q30421172 | Creating a community resource for protein science |
| Q45406845 | Critical role of Arg59 in the high-affinity gp120-binding region of CD4 for human immunodeficiency virus type 1 infection |
| Q35536516 | Crystal structure of a fully glycosylated HIV-1 gp120 core reveals a stabilizing role for the glycan at Asn262. |
| Q27639371 | Crystal structure of a human rhinovirus that displays part of the HIV-1 V3 loop and induces neutralizing antibodies against HIV-1 |
| Q42031529 | Crystal structures of human immunodeficiency virus type 1 (HIV-1) neutralizing antibody 2219 in complex with three different V3 peptides reveal a new binding mode for HIV-1 cross-reactivity |
| Q37356010 | Derivation and characterization of a simian immunodeficiency virus SIVmac239 variant with tropism for CXCR4. |
| Q36057328 | Design and characterization of a peptide mimotope of the HIV-1 gp120 bridging sheet |
| Q34094476 | Design of a non-glycosylated outer domain-derived HIV-1 gp120 immunogen that binds to CD4 and induces neutralizing antibodies |
| Q40430180 | Design, expression, and immunogenicity of a soluble HIV trimeric envelope fragment adopting a prefusion gp41 configuration |
| Q34626673 | Design, synthesis and biological evaluation of small molecule inhibitors of CD4-gp120 binding based on virtual screening |
| Q36279073 | Determination of protein-derived epitopes by mass spectrometry |
| Q55508034 | Differential functional phenotypes of two primary HIV-1 strains resulting from homologous point mutations in the LLP domains of the envelope gp41 intracytoplasmic domain. |
| Q38090682 | Discovery of ABT-263, a Bcl-family protein inhibitor: observations on targeting a large protein-protein interaction |
| Q27646546 | Discovery of Leukotriene A4 Hydrolase Inhibitors Using Metabolomics Biased Fragment Crystallography † |
| Q33780620 | Discovery of small-molecule human immunodeficiency virus type 1 entry inhibitors that target the gp120-binding domain of CD4. |
| Q34401027 | Disulfide bond that constrains the HIV-1 gp120 V3 domain is cleaved by thioredoxin |
| Q26772129 | Dynamic Viral Glycoprotein Machines: Approaches for Probing Transient States That Drive Membrane Fusion |
| Q79387613 | Dynamic domains and geometrical properties of HIV-1 gp120 during conformational changes induced by CD4 binding |
| Q39314021 | Efficiency of bridging-sheet recruitment explains HIV-1 R5 envelope glycoprotein sensitivity to soluble CD4 and macrophage tropism |
| Q30499561 | Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions |
| Q35062926 | Enhanced dynamics of HIV gp120 glycoprotein by small molecule binding |
| Q27641982 | Enhancing protein crystallization through precipitant synergy |
| Q40311336 | Entropy calculation of HIV-1 Env gp120, its receptor CD4, and their complex: an analysis of configurational entropy changes upon complexation |
| Q33839485 | Envelope glycoprotein determinants of neutralization resistance in a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2) derived by passage in monkeys |
| Q36155555 | Envelope variable region 4 is the first target of neutralizing antibodies in early simian immunodeficiency virus mac251 infection of rhesus monkeys |
| Q42959357 | Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1. |
| Q33504599 | Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways |
| Q45611333 | Evidence for Selection of more Adapted Human Immunodeficiency Virus Type 1 Recombinant Strains in a Dually Infected Transfusion Recipient |
| Q30157538 | Evolution rescues folding of human immunodeficiency virus-1 envelope glycoprotein GP120 lacking a conserved disulfide bond |
| Q37596817 | Evolutionary dynamics of the glycan shield of the human immunodeficiency virus envelope during natural infection and implications for exposure of the 2G12 epitope |
| Q36802333 | Exploiting the defensive sugars of HIV-1 for drug and vaccine design |
| Q21090507 | Few and far between: how HIV may be evading antibody avidity |
| Q28217208 | Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. |
| Q36386536 | Fluctuation dynamics analysis of gp120 envelope protein reveals a topologically based communication network |
| Q42712576 | Fold recognition of the human immunodeficiency virus type 1 V3 loop and flexibility of its crown structure during the course of adaptation to a host |
| Q33780529 | Functional chimeras of human immunodeficiency virus type 1 Gp120 and influenza A virus (H3) hemagglutinin |
| Q39365770 | Functional evolution of the HIV-1 envelope glycoprotein 120 association site of glycoprotein 41. |
| Q33780450 | Functional mimicry of a human immunodeficiency virus type 1 coreceptor by a neutralizing monoclonal antibody |
| Q53853233 | Fusion/entry inhibitors as therapies for HIV. |
| Q33719511 | Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies |
| Q92766714 | Glycosylation of viral surface proteins probed by mass spectrometry |
| Q28296162 | HIV entry inhibitors: mechanisms of action and resistance pathways |
| Q60920348 | HIV vaccines: Biological and clinical considerations |
| Q34864743 | HIV-1 envelope accessible surface and polarity: clade, blood, and brain |
| Q27011248 | HIV-1 envelope glycoprotein structure |
| Q29619017 | HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites |
| Q28086826 | HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth |
| Q41823383 | HIV-2 neutralization by intact V3-specific Fab fragments |
| Q26766153 | Harnessing the protective potential of HIV-1 neutralizing antibodies |
| Q27679031 | Heavy Chain-Only IgG2b Llama Antibody Effects Near-Pan HIV-1 Neutralization by Recognizing a CD4-Induced Epitope That Includes Elements of Coreceptor- and CD4-Binding Sites |
| Q38328705 | Heparan sulfate targets the HIV-1 envelope glycoprotein gp120 coreceptor binding site. |
| Q37179996 | Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India |
| Q45463275 | Highly conserved beta16/beta17 beta-hairpin structure in human immunodeficiency virus type 1 YU2 gp120 is critical for CCR5 binding |
| Q38014473 | Human immunodeficiency virus-1 gp120 V3 loop for anti-acquired immune deficiency syndrome drug discovery: computer-aided approaches to the problem solving |
| Q24679395 | Hyperglycosylated Mutants of Human Immunodeficiency Virus (HIV) Type 1 Monomeric gp120 as Novel Antigens for HIV Vaccine Design |
| Q39668082 | Identification and characterization of an immunogenic hybrid epitope formed by both HIV gp120 and human CD4 proteins |
| Q53851964 | Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. |
| Q47566053 | Identification of novel structural determinants in MW965 Env that regulate the neutralization phenotype and conformational masking potential of primary HIV-1 isolates |
| Q33984371 | Identification of two N-linked glycosylation sites within the core of the simian immunodeficiency virus glycoprotein whose removal enhances sensitivity to soluble CD4. |
| Q35708836 | Identifying epitopes of HIV-1 that induce protective antibodies |
| Q44646864 | Immunofocusing: antigen engineering to promote the induction of HIV-neutralizing antibodies |
| Q33262275 | Immunogenicity of a polyvalent HIV-1 candidate vaccine based on fourteen wild type gp120 proteins in golden hamsters |
| Q40561855 | Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity |
| Q34529347 | In vivo patterns of resistance to the HIV attachment inhibitor BMS-488043. |
| Q33392865 | Inducing cross-clade neutralizing antibodies against HIV-1 by immunofocusing |
| Q33725711 | Influence of disulfide-stabilized structure on the specificity of helper T-cell and antibody responses to HIV envelope glycoprotein gp120 |
| Q33614605 | Influence of novel CD4 binding-defective HIV-1 envelope glycoprotein immunogens on neutralizing antibody and T-cell responses in nonhuman primates |
| Q47118310 | Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations |
| Q35221774 | Insight derived from molecular dynamics simulations into molecular motions, thermodynamics and kinetics of HIV-1 gp120 |
| Q34490720 | Insights into the structure, correlated motions, and electrostatic properties of two HIV-1 gp120 V3 loops |
| Q28543396 | Integrated analysis of residue coevolution and protein structures capture key protein sectors in HIV-1 proteins |
| Q59358743 | Interdomain Stabilization Impairs CD4 Binding and Improves Immunogenicity of the HIV-1 Envelope Trimer |
| Q27678341 | Interfacial Cavity Filling To Optimize CD4–Mimetic Miniprotein Interactions with HIV-1 Surface Glycoprotein |
| Q34885869 | Isolate-specific differences in the conformational dynamics and antigenicity of HIV-1 gp120. |
| Q33740100 | Large-scale conformational sampling of proteins using temperature-accelerated molecular dynamics |
| Q34120786 | Local conformational stability of HIV-1 gp120 in unliganded and CD4-bound states as defined by amide hydrogen/deuterium exchange |
| Q37010292 | Localized changes in the gp120 envelope glycoprotein confer resistance to human immunodeficiency virus entry inhibitors BMS-806 and #155. |
| Q34792976 | Longitudinal Analysis of CCR5 and CXCR4 Usage in a Cohort of Antiretroviral Therapy-Naïve Subjects with Progressive HIV-1 Subtype C Infection. |
| Q54246851 | Mapping mutational effects along the evolutionary landscape of HIV envelope. |
| Q81155966 | Mechanism of membrane fusion by viral envelope proteins |
| Q33269695 | Mimotopes selected with antibodies from HIV-1-neutralizing long-term non-progressor plasma |
| Q40484043 | Modified HIV envelope proteins with enhanced binding to neutralizing monoclonal antibodies |
| Q41137332 | Molecular construction of HIV-gp120 discontinuous epitope mimics by assembly of cyclic peptides on an orthogonal alkyne functionalized TAC-scaffold. |
| Q57897038 | Molecular mechanism of HIV-1 gp120 mutations that reduce CD4 binding affinity |
| Q44649287 | Molecular motions of human HIV-1 gp120 envelope glycoproteins |
| Q21559473 | Molecular recognition of CCR5 by an HIV-1 gp120 V3 loop |
| Q24616040 | Molecular recognition of CXCR4 by a dual tropic HIV-1 gp120 V3 loop |
| Q35066154 | Monoclonal antibodies for the structural analysis of the Na+/H+ antiporter NhaA from Escherichia coli |
| Q34347265 | Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein |
| Q42219237 | NMR observation of HIV-1 gp120 conformational flexibility resulting from V3 truncation |
| Q30989881 | NMR structural analysis of a peptide mimic of the bridging sheet of HIV-1 gp120 in methanol and water |
| Q33733243 | Naturally occurring variability in the envelope glycoprotein of HIV-1 and development of cell entry inhibitors |
| Q39704592 | Neutralization efficiency is greatly enhanced by bivalent binding of an antibody to epitopes in the V4 region and the membrane-proximal external region within one trimer of human immunodeficiency virus type 1 glycoproteins |
| Q36843543 | Neutralization of HIV-1 by redirection of natural antibodies |
| Q37059618 | Neutralization of Infectivity of Diverse R5 Clinical Isolates of Human Immunodeficiency Virus Type 1 by gp120-Binding 2′F-RNA Aptamers |
| Q35857268 | Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection |
| Q35745453 | Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity |
| Q37305770 | Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy |
| Q43124783 | Optimization of human immunodeficiency virus type 1 envelope glycoproteins with V1/V2 deleted, using virus evolution |
| Q41965065 | Peptides presenting the binding site of human CD4 for the HIV-1 envelope glycoprotein gp120. |
| Q38189746 | Physicochemical bases for protein folding, dynamics, and protein-ligand binding |
| Q44567176 | Picking the lock with a hairpin. Did HIV-1 learn the art from chemokines? |
| Q34374835 | Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial |
| Q30360451 | Production and characterization of monoclonal antibodies sensitive to conformation in the 5HT2c serotonin receptor. |
| Q34453555 | Progress in targeting HIV-1 entry. |
| Q37572718 | Protein dynamics and motions in relation to their functions: several case studies and the underlying mechanisms |
| Q37950254 | Protein intrinsic disorder as a flexible armor and a weapon of HIV-1. |
| Q35199283 | Putative rhesus macaque germline predecessors of human broadly HIV-neutralizing antibodies: differences from the human counterparts and implications for HIV-1 vaccine development |
| Q40325417 | Quaternary contact in the initial interaction of CD4 with the HIV-1 envelope trimer |
| Q33640144 | R5 clade C SHIV strains with tier 1 or 2 neutralization sensitivity: tools to dissect env evolution and to develop AIDS vaccines in primate models |
| Q36811996 | Range of CD4-Bound Conformations of HIV-1 gp120, as Defined Using Conditional CD4-Induced Antibodies |
| Q34342950 | Rapid progression to simian AIDS can be accompanied by selection of CD4-independent gp120 variants with impaired ability to bind CD4. |
| Q34174815 | Rational design and characterization of the novel, broad and potent bispecific HIV-1 neutralizing antibody iMabm36. |
| Q45052086 | Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes |
| Q34042642 | Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections |
| Q27642457 | Recurring conformation of the human immunodeficiency virus type 1 gp120 V3 loop |
| Q40204965 | Resistance of HIV-1 to the broadly HIV-1-neutralizing, anti-carbohydrate antibody 2G12. |
| Q38774625 | Restraining the conformation of HIV-1 gp120 by removing a flexible loop |
| Q40638638 | Role of the gp120 inner domain beta-sandwich in the interaction between the human immunodeficiency virus envelope glycoprotein subunits |
| Q88314365 | Roles of conserved tryptophans in trimerization of HIV-1 membrane-proximal external regions: Implications for virucidal design via alchemical free-energy molecular simulations |
| Q31112205 | Scaffold optimization in discontinuous epitope containing protein mimics of gp120 using smart libraries |
| Q37002237 | Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120. |
| Q36299747 | Spontaneous rearrangement of the β20/β21 strands in simulations of unliganded HIV-1 glycoprotein, gp120 |
| Q47342775 | Stability and Water Accessibility of the Trimeric Membrane Anchors of the HIV-1 Envelope Spikes. |
| Q35857416 | Stability of a receptor-binding active human immunodeficiency virus type 1 recombinant gp140 trimer conferred by intermonomer disulfide bonding of the V3 loop: differential effects of protein disulfide isomerase on CD4 and coreceptor binding |
| Q34361680 | Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. |
| Q34299053 | Stabilized HIV-1 envelope glycoprotein trimers lacking the V1V2 domain, obtained by virus evolution |
| Q28534454 | Stabilizing exposure of conserved epitopes by structure guided insertion of disulfide bond in HIV-1 envelope glycoprotein |
| Q92482128 | Strain-Dependent Activation and Inhibition of Human Immunodeficiency Virus Entry by a Specific PF-68742 Stereoisomer |
| Q40796326 | Structural Basis for Species Selectivity in the HIV-1 gp120-CD4 Interaction: Restoring Affinity to gp120 in Murine CD4 Mimetic Peptides |
| Q27658449 | Structural Basis of Immune Evasion at the Site of CD4 Attachment on HIV-1 gp120 |
| Q30393415 | Structural analysis of a highly glycosylated and unliganded gp120-based antigen using mass spectrometry |
| Q27643185 | Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120 |
| Q38288521 | Structural characterization of a 2'F-RNA aptamer that binds a HIV-1 SU glycoprotein, gp120. |
| Q34064787 | Structural determinants for affinity enhancement of a dual antagonist peptide entry inhibitor of human immunodeficiency virus type-1. |
| Q56790128 | Structural dynamics of V3 loop with different electrostatics: implications on co-receptor recognition: a molecular dynamics study of HIV gp120 |
| Q62572413 | Structural elements of primary CCR5-using HIV-1 gp120 proteins influencing sensitivity and resistance to the broadly neutralizing monoclonal antibody b12 |
| Q21131394 | Structural mechanism of trimeric HIV-1 envelope glycoprotein activation |
| Q27327645 | Structural plasticity and conformational transitions of HIV envelope glycoprotein gp120 |
| Q41972387 | Structure and design of broadly-neutralizing antibodies against HIV. |
| Q36856960 | Structure and function of the HIV envelope glycoprotein as entry mediator, vaccine immunogen, and target for inhibitors |
| Q27649247 | Structure of Antibody F425-B4e8 in Complex with a V3 Peptide Reveals a New Binding Mode for HIV-1 Neutralization |
| Q27644478 | Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9 |
| Q27658989 | Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility |
| Q29619014 | Structure of a V3-containing HIV-1 gp120 core |
| Q27660384 | Structure of a clade C HIV-1 gp120 bound to CD4 and CD4-induced antibody reveals anti-CD4 polyreactivity |
| Q34045535 | Structure of the Fab fragment of F105, a broadly reactive anti-human immunodeficiency virus (HIV) antibody that recognizes the CD4 binding site of HIV type 1 gp120. |
| Q42882532 | Structure of trimeric HIV-1 envelope glycoproteins. |
| Q27678493 | Structure-Based Design, Synthesis, and Characterization of Dual Hotspot Small-Molecule HIV-1 Entry Inhibitors |
| Q36868014 | Structure-activity relationships in the binding of chemically derivatized CD4 to gp120 from human immunodeficiency virus |
| Q30358736 | Structure-based design, synthesis and validation of CD4-mimetic small molecule inhibitors of HIV-1 entry: conversion of a viral entry agonist to an antagonist. |
| Q44572417 | Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition. |
| Q34128200 | Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold. |
| Q37704735 | Subtype-specific conservation of isoleucine 309 in the envelope V3 domain is linked to immune evasion in subtype C HIV-1 infection |
| Q93085697 | Synthesis of Modular Building Blocks using Glycosyl Phosphate Donors for the Construction of Asymmetric N-Glycans |
| Q42323642 | Systematic protein-protein docking and molecular dynamics studies of HIV-1 gp120 and CD4: insights for new drug development |
| Q34485260 | The B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian seroconverter |
| Q21559515 | The SIV surface spike imaged by electron tomography: one leg or three? |
| Q34342352 | The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120. |
| Q39686562 | The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor |
| Q36155396 | The development of CD4 binding site antibodies during HIV-1 infection |
| Q39259705 | The evolutionary significance of certain amino acid substitutions and their consequences for HIV-1 immunogenicity toward HLA's A*0201 and B*27. |
| Q36607016 | The highly conserved layer-3 component of the HIV-1 gp120 inner domain is critical for CD4-required conformational transitions. |
| Q37099851 | The human immunodeficiency virus type 1 envelope spike of primary viruses can suppress antibody access to variable regions |
| Q37667754 | The implications of patterns in HIV diversity for neutralizing antibody induction and susceptibility. |
| Q33566030 | The importance of being flexible: the case of basic region leucine zipper transcriptional regulators |
| Q37428017 | The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. |
| Q44433968 | The investigations on HIV-1 gp120 bound with BMS-488043 by using docking and molecular dynamics simulations |
| Q34341843 | The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. |
| Q45662866 | The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4. |
| Q33953062 | The role of the third beta strand in gp120 conformation and neutralization sensitivity of the HIV-1 primary isolate DH012 |
| Q30430240 | Three-Dimensional Visualizations in Teaching Genomics and Bioinformatics: Mutations in HIV Envelope Proteins and Their Consequences for Vaccine Design. |
| Q37612615 | Tyrosine sulfation in the second variable loop (V2) of HIV-1 gp120 stabilizes V2-V3 interaction and modulates neutralization sensitivity |
| Q37221499 | Tyrosine-sulfated V2 peptides inhibit HIV-1 infection via coreceptor mimicry. |
| Q41932027 | Unique binding modes for the broad neutralizing activity of single-chain variable fragments (scFv) targeting CD4-induced epitopes |
| Q35857683 | Unique mutational patterns in the envelope alpha 2 amphipathic helix and acquisition of length in gp120 hypervariable domains are associated with resistance to autologous neutralization of subtype C human immunodeficiency virus type 1. |
| Q27678226 | Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops |
| Q30480515 | Use of the quartz crystal microbalance to monitor ligand-induced conformational rearrangements in HIV-1 envelope protein gp120. |
| Q35103647 | Vaccine for AIDS and Ebola virus infection |
| Q34332708 | Vaccines for the prevention of HIV-1 disease |
| Q33707333 | Variants of human immunodeficiency virus type 1 that efficiently use CCR5 lacking the tyrosine-sulfated amino terminus have adaptive mutations in gp120, including loss of a functional N-glycan |
| Q27676728 | Viral Escape from Neutralizing Antibodies in Early Subtype A HIV-1 Infection Drives an Increase in Autologous Neutralization Breadth |
| Q35192660 | epitopes immediately below the base of the V3 loop of gp120 as targets for the initial autologous neutralizing antibody response in two HIV-1 subtype B-infected individuals |
| Q33348658 | sCD4-17b bifunctional protein: extremely broad and potent neutralization of HIV-1 Env pseudotyped viruses from genetically diverse primary isolates |
Search more.